PUBLIC COMPANY
saveTris Pharma Inc
updated 12d ago
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval88 co-mentions · 44 sources
- drugHYDROCODONE BITARTRATE AND ACETAMINOPHEN63 co-mentions · 21 sources
- tagSmall Molecule44 co-mentions · 44 sources
- drugDYANAVEL XR 2028 co-mentions · 14 sources
- drugDYANAVEL XR28 co-mentions · 14 sources
- drughydrocodone bitartrate ER21 co-mentions · 21 sources
- drugHYDROCODONE BITARTRATE AND IBUPROFEN21 co-mentions · 21 sources
- drugHYDROCODONE BITARTRATE21 co-mentions · 21 sources
pipeline
8
marketed
4
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(8)
pipeline depth8 products
1Phase 21Phase 34Marketed1pre_registration1Unknown
Marketed
(chlorpheniramine + hydrocodone) ER
Nasopharyngitis (Common Cold)
MarketedOnyda XR
Attention Deficit Hyperactivity Disorder (ADHD)
MarketedQuillivant XR
Attention Deficit Hyperactivity Disorder (ADHD)
Marketedamfetamine ER
Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3cebranopadol
Pain
Nociceptin receptorOpioid receptors; mu/kappa/delta
Phase 2TRN-261
Pain
drugHYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX EXTENDED-RELEASE
pre_registrationTRN-257
Idiopathic Hypersomnia (IH)
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trialPlus, news about Insilico, Ipsen, Q32 Bio, GSK’s Jemperli, Drug Farm and Padcev. ❌ FDA rejects Tris Pharma’s narcolepsy drug: Its rejection letter said that “additional information will be necessar…endpoints · 29d ago
comments(0)
5-min edit window · permanent after that